Cencora vs Dr Reddys Laboratories
COR and RDY side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COR and RDY compare
Cencora grew revenue faster over the last twelve months (5.1% versus 3.2% for Dr Reddys Laboratories).
Dr Reddys Laboratories keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 0.79% at Cencora.
Cencora pays a dividend yielding 0.73%; Dr Reddys Laboratories does not pay one.
Cencora scores higher on the StockData Score (15 against 7 for Dr Reddys Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COR | RDY |
|---|---|---|
| Size and price | ||
| Market cap | $63.1B | – |
| Share price | $330.84 | $14.17 |
| Change, 1 year | −0.70% | 5.7% |
| Change, 5 years | 159% | 11.8% |
| Beta (5Y) | 0.33 | 0.37 |
| Employees | 51K | – |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 5 (better) | 2 |
| Health score | 2 | 4 (better) |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 24.6× | – |
| P/S | 0.2× | – |
| P/B | 20.7× | – |
| EV/EBITDA | 17.7× | – |
| P/FCF | 15.5× | – |
| FCF yield | 6.4% | – |
| Fair value | $287.88 | – |
| Margin of safety | −14.9% | – |
| Growth | ||
| Revenue growth (TTM) | 5.1% (better) | 3.2% |
| Revenue growth, 5Y average | 11.1% | 12.1% (better) |
| Net income growth (TTM) | 38.3% (better) | −24.2% |
| EPS growth (TTM) | 38.6% (better) | −24.1% |
| EPS growth, 5Y average | – | 19.9% |
| Profitability | ||
| Gross margin | 4.0% | 52.8% (better) |
| Operating margin | 0.91% | 15.0% (better) |
| Net margin | 0.79% | 12.8% (better) |
| FCF margin | 1.2% | 10.0% (better) |
| Return on equity | 104% (better) | 12.1% |
| Return on invested capital | 22.3% (better) | 9.7% |
| Financial health | ||
| Debt / equity | 3.84 | 0.21 (better) |
| Net debt / EBITDA | 2.18 | 0.87 (better) |
| Interest coverage | – | 13.5× |
| Current ratio | 0.93 | 1.80 (better) |
| Altman Z-score | 4.66 | – |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.73% | – |
| Payout ratio | 17.8% | 15.5% |
| Years of dividend growth | 16 (better) | 0 |
| Dividend growth, 5Y average | 5.8% | 9.9% (better) |
| Buyback yield | 1.6% | – |
| Shareholder yield | 2.3% | – |
| Ownership | ||
| Held by institutions | 96.1% | 15.1% |
| Held by insiders | 5.4% | 13.6% |
| Insider net buying, 12 months | −$12.4M | – |
| Short interest, % of float | 2.2% | – |
Go deeper
- COR stock overview
- COR income statement
- COR valuation and score
- RDY stock overview
- RDY income statement
- RDY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.